FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002561625> ?p ?o ?g. }

• W2002561625 endingPage "30360" @default.
• W2002561625 startingPage "30352" @default.
• W2002561625 abstract "Cholangiocytes, the epithelial cells lining the bile ducts in the liver, are periodically exposed to potentially injurious microbes and/or microbial products. As a result, cholangiocytes actively participate in microbe-associated, hepatic proinflammatory responses. We previously showed that infection of cultured human cholangiocytes with the protozoan parasite, Cryptosporidium parvum, or treatment with Gram-negative bacteria-derived LPS, activates NFκB in a myeloid differentiation 88 (MyD88)-dependent manner. Here, we describe a novel signaling pathway initiated by Toll-like receptors (TLRs) involving the small GTPase, Ras, that mediates cholangiocyte proinflammatory cytokine production and induction of cholangiocyte proliferation. Using cultured human cholangiocytes and a Ras activation assay, we found that agonists of plasma membrane TLRs (TLR 1, 2, 4, 5, and 6) rapidly (<10 min) activated N-Ras, but not other p21 Ras isoforms, resulting in the rapid (<15 min) phosphorylation of the downstream Ras effector, ERK1/2. RNA interference-induced depletion of TRAF6, a downstream effector of MyD88 and known activator of MAPK signaling, had no effect on N-Ras activation. Following N-Ras activation the proinflammatory cytokine, IL6, is rapidly secreted. Using a luciferase reporter, we demonstrated that LPS treatment induced IL6 promoter-driven luciferase which was suppressed using MEK/ERK pharmacologic inhibitors (PD98059 or U0126) and RNAi-induced depletion of N-Ras. Finally, we showed that LPS increased cholangiocyte proliferation (1.5-fold), which was inhibited by depletion of N-Ras; TLR agonist-induced proliferation was also inhibited following pretreatment with an IL6 receptor-blocking antibody. Together, our results support a novel signaling axis involving microbial activation of N-Ras likely involved in the cholangiocyte pathogen-induced proinflammatory response. Cholangiocytes, the epithelial cells lining the bile ducts in the liver, are periodically exposed to potentially injurious microbes and/or microbial products. As a result, cholangiocytes actively participate in microbe-associated, hepatic proinflammatory responses. We previously showed that infection of cultured human cholangiocytes with the protozoan parasite, Cryptosporidium parvum, or treatment with Gram-negative bacteria-derived LPS, activates NFκB in a myeloid differentiation 88 (MyD88)-dependent manner. Here, we describe a novel signaling pathway initiated by Toll-like receptors (TLRs) involving the small GTPase, Ras, that mediates cholangiocyte proinflammatory cytokine production and induction of cholangiocyte proliferation. Using cultured human cholangiocytes and a Ras activation assay, we found that agonists of plasma membrane TLRs (TLR 1, 2, 4, 5, and 6) rapidly (<10 min) activated N-Ras, but not other p21 Ras isoforms, resulting in the rapid (<15 min) phosphorylation of the downstream Ras effector, ERK1/2. RNA interference-induced depletion of TRAF6, a downstream effector of MyD88 and known activator of MAPK signaling, had no effect on N-Ras activation. Following N-Ras activation the proinflammatory cytokine, IL6, is rapidly secreted. Using a luciferase reporter, we demonstrated that LPS treatment induced IL6 promoter-driven luciferase which was suppressed using MEK/ERK pharmacologic inhibitors (PD98059 or U0126) and RNAi-induced depletion of N-Ras. Finally, we showed that LPS increased cholangiocyte proliferation (1.5-fold), which was inhibited by depletion of N-Ras; TLR agonist-induced proliferation was also inhibited following pretreatment with an IL6 receptor-blocking antibody. Together, our results support a novel signaling axis involving microbial activation of N-Ras likely involved in the cholangiocyte pathogen-induced proinflammatory response." @default.
• W2002561625 created "2016-06-24" @default.
• W2002561625 creator A5010082559 @default.
• W2002561625 creator A5015968427 @default.
• W2002561625 creator A5025328999 @default.
• W2002561625 creator A5040651926 @default.
• W2002561625 creator A5048820653 @default.
• W2002561625 creator A5074947825 @default.
• W2002561625 date "2011-09-01" @default.
• W2002561625 modified "2023-10-15" @default.
• W2002561625 title "Cholangiocyte N-Ras Protein Mediates Lipopolysaccharide-induced Interleukin 6 Secretion and Proliferation" @default.
• W2002561625 cites W179818011 @default.
• W2002561625 cites W1852817901 @default.
• W2002561625 cites W1893408494 @default.
• W2002561625 cites W1971013426 @default.
• W2002561625 cites W1973872654 @default.
• W2002561625 cites W1976086500 @default.
• W2002561625 cites W1986224066 @default.
• W2002561625 cites W1993561986 @default.
• W2002561625 cites W2003943384 @default.
• W2002561625 cites W2004465286 @default.
• W2002561625 cites W2004862616 @default.
• W2002561625 cites W2006289424 @default.
• W2002561625 cites W2006428522 @default.
• W2002561625 cites W2008487299 @default.
• W2002561625 cites W2008570049 @default.
• W2002561625 cites W2008903449 @default.
• W2002561625 cites W2012813036 @default.
• W2002561625 cites W2014857894 @default.
• W2002561625 cites W2027359667 @default.
• W2002561625 cites W2031345904 @default.
• W2002561625 cites W2033445369 @default.
• W2002561625 cites W2040423355 @default.
• W2002561625 cites W2041967811 @default.
• W2002561625 cites W2042400975 @default.
• W2002561625 cites W2053046804 @default.
• W2002561625 cites W2056692303 @default.
• W2002561625 cites W2070210483 @default.
• W2002561625 cites W2083112106 @default.
• W2002561625 cites W2084269584 @default.
• W2002561625 cites W2101363646 @default.
• W2002561625 cites W2110058830 @default.
• W2002561625 cites W2119013116 @default.
• W2002561625 cites W2121596041 @default.
• W2002561625 cites W2135070276 @default.
• W2002561625 cites W2143668307 @default.
• W2002561625 cites W2144038313 @default.
• W2002561625 cites W2161754722 @default.
• W2002561625 cites W2162714126 @default.
• W2002561625 doi "https://doi.org/10.1074/jbc.m111.269464" @default.
• W2002561625 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3162394" @default.
• W2002561625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21757746" @default.
• W2002561625 hasPublicationYear "2011" @default.
• W2002561625 type Work @default.
• W2002561625 sameAs 2002561625 @default.
• W2002561625 citedByCount "60" @default.
• W2002561625 countsByYear W20025616252012 @default.
• W2002561625 countsByYear W20025616252013 @default.
• W2002561625 countsByYear W20025616252014 @default.
• W2002561625 countsByYear W20025616252015 @default.
• W2002561625 countsByYear W20025616252016 @default.
• W2002561625 countsByYear W20025616252017 @default.
• W2002561625 countsByYear W20025616252018 @default.
• W2002561625 countsByYear W20025616252019 @default.
• W2002561625 countsByYear W20025616252020 @default.
• W2002561625 countsByYear W20025616252021 @default.
• W2002561625 countsByYear W20025616252022 @default.
• W2002561625 crossrefType "journal-article" @default.
• W2002561625 hasAuthorship W2002561625A5010082559 @default.
• W2002561625 hasAuthorship W2002561625A5015968427 @default.
• W2002561625 hasAuthorship W2002561625A5025328999 @default.
• W2002561625 hasAuthorship W2002561625A5040651926 @default.
• W2002561625 hasAuthorship W2002561625A5048820653 @default.
• W2002561625 hasAuthorship W2002561625A5074947825 @default.
• W2002561625 hasBestOaLocation W20025616251 @default.
• W2002561625 hasConcept C134018914 @default.
• W2002561625 hasConcept C164027704 @default.
• W2002561625 hasConcept C203014093 @default.
• W2002561625 hasConcept C2776914184 @default.
• W2002561625 hasConcept C2780186670 @default.
• W2002561625 hasConcept C51785407 @default.
• W2002561625 hasConcept C57074206 @default.
• W2002561625 hasConcept C62478195 @default.
• W2002561625 hasConcept C86803240 @default.
• W2002561625 hasConcept C95444343 @default.
• W2002561625 hasConceptScore W2002561625C134018914 @default.
• W2002561625 hasConceptScore W2002561625C164027704 @default.
• W2002561625 hasConceptScore W2002561625C203014093 @default.
• W2002561625 hasConceptScore W2002561625C2776914184 @default.
• W2002561625 hasConceptScore W2002561625C2780186670 @default.
• W2002561625 hasConceptScore W2002561625C51785407 @default.
• W2002561625 hasConceptScore W2002561625C57074206 @default.
• W2002561625 hasConceptScore W2002561625C62478195 @default.
• W2002561625 hasConceptScore W2002561625C86803240 @default.
• W2002561625 hasConceptScore W2002561625C95444343 @default.
• W2002561625 hasIssue "35" @default.
• W2002561625 hasLocation W20025616251 @default.
• W2002561625 hasLocation W20025616252 @default.

• next